Will this outgrow the OTC? ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏



 

_You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS. If you no longer wish to receive
these partner emails, please unsubscribe
[[link removed]]
here. This message is from Huge Alerts._

 

-------------------------

[BSEM] [[link removed]]

IS BSEM ABOUT TO OUTGROW THE OTC? PROFITABLE EXECUTION, BREAKTHROUGH
CLINICAL DATA, AND A $25.50 ANALYST TARGET SUGGEST A MAJOR RE-RATE
COULD BE COMING!

BioStem Technologies (BSEM) continues to separate itself from the
noise in MedTech by delivering real earnings power. 

In Q3 2025, the company reported $2.7 million in adjusted EBITDA—its
seventh straight profitable quarter—while maintaining strong margins
and a solid cash position. Even with pricing pressure across the
wound-care industry, BSEM’s vertically integrated, GMP-compliant
platform has allowed it to grow volume, protect profitability, and
invest in long-term expansion.

The real potential upside lies in BioStem’s clinical and market
momentum. BioREtain® allografts have demonstrated superior
wound-closure outcomes in peer-reviewed trials, targeting a global
wound-care market measured in the tens of billions. 

With new access points through federal programs, state Medicaid, and
hospitals—and a planned Nasdaq uplisting in 2026—BSEM is building
the foundation for institutional adoption and accelerated growth.
Analysts are already taking notice with a $25.50 price target that
implies meaningful upside from current levels.

Discover why BSEM is emerging as one of the most compelling profitable
MedTech stories in 2026 [[link removed]]

We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive
compensation in connection with the purchase or sale of the securities
of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists
of up to $6,500 and was received/will be received from Sideways
Frequency.

This compensation should not be considered as an endorsement of the
securities of BioStem Technologies Inc. (OTC: BSEM) and we are not
responsible for any errors or omissions in any information provided
about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge
Alerts.

We encourage you to conduct your own due diligence and research before
making any investment decisions. You should also consult with a
financial advisor before making any investment decisions.

This disclosure is made as of 01/16/2026.

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the
Markets. For more information about our privacy practices, please
review our Privacy Policy
[[link removed]]
or our Legal Notices.
[[link removed]]


Behind the Markets
[[link removed]]

_You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these partner emails, please unsubscribe here
[[link removed]]._


TODAY'S BONUS CONTENT: [Revealed] The $100 Starlink Pre-IPO Jackpot!
[[link removed]]